Sign In
Buy ITCI
$131.87
+0 (+0%)
At Close: Jul 01, 2025
3 Biotech Stocks Most Wall Street Analysts Are Bullish About
10:31am, Monday, 18'th Dec 2023
Here we present three biotech stocks, CRSP, ITCI and DVAX, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024, backed by strong fundamentals.
The Right Play On Intra-Cellular Therapies
11:49am, Monday, 20'th Nov 2023
Intra-Cellular Therapies, Inc. is a mid-cap biopharmaceutical company focused on developing treatments for neuropsychiatric and neurological disorders. The company's commercial asset, Caplyta, has ach
Intra-Cellular's Caplyta Is Well On Its Way To Being A Mental Health Blockbuster
05:47am, Monday, 13'th Nov 2023
Intra-Cellular Therapies shows strong financial growth, driven by Caplyta sales, with improved operational efficiency and reduced net losses. Caplyta's success in schizophrenia and bipolar depression,
Intra-Cellular (ITCI) Q3 Earnings Top, Product Sales View Raised
01:32pm, Friday, 03'rd Nov 2023
Intra-Cellular (ITCI) third-quarter 2023 earnings and revenues beat estimates. Caplyta sales continue to drive growth.
Intra-Cellular Therapies, Inc. (ITCI) Q3 2023 Earnings Call Transcript
03:15pm, Thursday, 02'nd Nov 2023
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Juan Sanchez – Head-Investor Relations Sharon Mates – Chairman and C
Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences
08:00am, Tuesday, 31'st Oct 2023
NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv
Intra-Cellular Therapies to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
08:00am, Wednesday, 20'th Sep 2023
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ner
Intra-Cellular Therapies to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
08:00am, Tuesday, 05'th Sep 2023
NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ner
Intra-Cellular Therapies: Caplyta's Rise And A Promising Pipeline
10:29am, Saturday, 12'th Aug 2023
Intra-Cellular Therapies' main drug, Caplyta, has been successful in treating neuropsychiatric conditions and has shown potential in addressing mixed features in mood disorders. Q2 2023 earnings repor
Intra-Cellular (ITCI) Q2 Earnings & Sales Top, '23 View Raised
09:47am, Friday, 04'th Aug 2023
Intra-Cellular (ITCI) reports better-than-expected second-quarter results. Caplyta sales continue to drive growth.
Intra-Cellular Therapies to Present at the Canaccord Genuity 43rd Annual Growth Conference
08:00am, Friday, 04'th Aug 2023
NEW YORK, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv
Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates
10:31am, Thursday, 03'rd Aug 2023
Intra-Cellular Therapies (ITCI) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $0.92 per share a year ago.
Intra-Cellular Therapies to Host Second Quarter 2023 Financial Results Conference Call and Webcast
08:00am, Friday, 28'th Jul 2023
NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ner
Intra-Cellular Therapies: Depression Data Boosts Investment Prospects (Rating Upgrade)
07:51pm, Thursday, 25'th May 2023
Intra-Cellular's drug Caplyta (lumateperone) is advancing through trials for major depressive disorder (MDD), expanding its approved uses beyond schizophrenia and bipolar depression. Caplyta faces exc
Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences
08:00am, Tuesday, 02'nd May 2023
NEW YORK, May 02, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervo
